CSIMarket
 
Azenta Inc   (NASDAQ: AZTA)
 

Azenta Inc's Customers Performance

AZTA



 
AZTA's Source of Revenues During the corresponding time, Azenta Inc recorded a revenue increase by 0.8 % year on year, sequentially revenue fell by -2.49 %. While revenue at the Azenta Inc 's corporate clients

List of AZTA Customers




for the same period Azenta Inc recorded revenue increase by 0.8 % year on year, sequentially revenue fell by -2.49 %.

List of AZTA Customers

Azenta Inc's Business Units
Multiomics    141.5 % of total Revenue
Core Products    96.91 % of total Revenue
Sample Repository Services    25.54 % of total Revenue
Sample Management Solutions    174.13 % of total Revenue
United States    181.87 % of total Revenue
China    37.22 % of total Revenue
United Kingdom    22.55 % of total Revenue
Rest of Europe    17.96 % of total Revenue
Asia Pacific Excluding China    5.23 % of total Revenue
Other    2.84 % of total Revenue
Product    83.3 % of total Revenue
Service    232.33 % of total Revenue
Sample Repository Solutions    77.21 % of total Revenue
Europe    57.18 % of total Revenue
Asia Pacific, Excluding China    13.96 % of total Revenue






Azenta Inc's Comment on Sales, Marketing and Customers



The company provides sample management and automated storage systems, genomic services, sample consumables, informatics and data software, and sample repository services to pharmaceutical, biotechnology, and life sciences research institutions worldwide. Its offerings support customers throughout the sample life cycle, including research, clinical development, and commercialization. The company operates in approximately 95 countries, with a presence in North America, Asia, and Europe. It focuses on the life sciences markets, having divested its semiconductor businesses and pursuing the sale of its B Medical Systems business to concentrate on its Sample Management Solutions and Multiomics segments.





Azenta Inc’s Comment on Sales, Marketing and Customers


The company provides sample management and automated storage systems, genomic services, sample consumables, informatics and data software, and sample repository services to pharmaceutical, biotechnology, and life sciences research institutions worldwide. Its offerings support customers throughout the sample life cycle, including research, clinical development, and commercialization. The company operates in approximately 95 countries, with a presence in North America, Asia, and Europe. It focuses on the life sciences markets, having divested its semiconductor businesses and pursuing the sale of its B Medical Systems business to concentrate on its Sample Management Solutions and Multiomics segments.








AZTA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Azenta Inc 1,529.75 595.46 -178.20 3,000
SUBTOTAL 0.00 0.00 0.00 -

Sources: Azenta Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Azenta Inc’s corporate clients.
For your research, we’ve provided 9 tables on Azenta Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.